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Sir,
In their concise review on evolving treatment strategies for
myeloma, Morgan and Davies (2005) stated that ‘early death was,
and still is, a significant problem, and addressing the causes of this
is important including early diagnosis, the treatment of infection,
hydration and the choice of the most appropriate chemotherapy’.
The most common presenting symptoms of the disease are fatigue,
bone pain and recurrent infections. The latest classification
system, recently released from The International Myeloma Work-
ing Group (2003), highlighted the importance to distinguish
between asymptomatic and overt myeloma, because only the
latter requires active treatment. According to this statement, the
biological activity of the disease, more than the tumour mass,
is the foremost guide to the therapy. The related organ or tissue
impairment (ROTI) that meets the criterion for the diagnosis
consists of hypercalcemia, renal insufficiency, anaemia or bone
lesions (a group of findings referred to as CRAB). However, we
need to understand that some of the clinical features of the disease,
as the degree of anaemia, are not completely explained by the
plasma cellular infiltrates or paraprotein secretion. Although
uncommonly, myeloma can present as fever of unknown origin
(FUO) (Mueller et al, 2002; Lambotte et al, 2003). In these cases the
fever is attributable to the disease itself, and indeed no infections
are demonstrable, even with extensive work-up. Moreover, the
fever cannot be abated with antibiotics although chemotherapy
works well (Mumoli et al, 2004). It is not already known if the
modulation of the interaction between the neoplastic clone and
the marrow microenvironment, as is the case during therapy
with bortezomib, could reverse this kind of presentation; this
could in turn result in delaying chemotherapy, at least in patients
not eligible for transplantation procedures. Morgan and Davies
conclude saying that in the future it will be desirable to describe
myeloma as a treatable disease with prolonged survival and
good quality of life if the correct treatment decisions are made.
We agree with this and we add, moreover, if the correct diagnosis
has also been made. We therefore suggest that FUO should
be mentioned as an indication for diagnosis and therapy in
myeloma patients.
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